Alkem Labs Q3 FY26 Revenue Up 10.7% to ₹3,737 Crore; Acquires Majority Stake in Occlutech
Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore, up 10.7% YoY. International sales surged 26.6% YoY. The company announced plans to acquire a majority stake in Occlutech Holding AG, a global medical devices company specializing in cardiac implants, to expand its Medtech business.
The acquisition of a significant stake in a global medical device company like Occlutech is a major strategic development that is expected to have a substantial long-term impact on Alkem Laboratories' business diversification and growth prospects.
The company reported strong revenue growth driven by both domestic and international businesses. The acquisition of a majority stake in Occlutech is a strategic move expected to drive future growth in the medical devices segment.
Alkem Laboratories Limited announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a total revenue from operations of ₹37,368 million (₹3,736.8 crore), marking a 10.7% year-on-year growth.
In Q3 FY26, India sales were ₹24,959 million (₹2,495.9 crore), a 5.5% increase year-on-year, contributing 67.2% to total sales. International sales grew by 26.6% year-on-year to ₹12,157 million (₹1,215.7 crore), with US sales contributing ₹7,533 million (up 18.8% YoY) and Non-US sales at ₹4,624 million (up 41.6% YoY).
Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) stood at ₹8,280 million (₹828 crore), a 9.0% year-on-year increase, with an EBITDA margin of 22.2%. Profit Before Tax (after exceptional item) was ₹7,812 million (₹781.2 crore), up 6.9% YoY. Net Profit after Non-Controlling interest was ₹6,360 million (₹636 crore), a 1.6% increase YoY.
An exceptional item of ₹528 million was recorded due to the notification by the Government of India regarding the four Labour Codes. R&D expenses for the quarter were ₹1,390 million, representing 3.7% of total revenue.
In a significant strategic move, Alkem MedTech Pvt Ltd, a wholly-owned subsidiary, has executed a binding term sheet to acquire a majority stake in Occlutech Holding AG, a Switzerland-headquartered medical devices company specializing in minimally invasive cardiac implants. This acquisition aims to establish a global footprint in medical devices, with Occlutech being the third-largest global player in its segment.
Dr. Vikas Gupta, CEO of Alkem, commented that the company delivered a stable performance in Q3, driven by strong domestic and international business fundamentals, and is on track to meet its full-year guidance. The planned launch of GLP-1 semaglutide in March 2026 is expected to be a key growth driver. Sandeep Singh, Managing Director, highlighted the strategic importance of the Occlutech acquisition for expanding into cardiovascular and orthopaedics, and expects Alkem MedTech to become a significant growth pillar alongside Enzene Biosciences.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.